HIV-Associated Facial Lipoatrophy

James, J; Carruthers, Alastair; Carruthers, Jean

doi:10.1097/00042728-200211000-00002

Cited by 34 publications

(74 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While a dexterous employment of proper injection technique is paramount, it is equally important to understand the aesthetic principles of beauty; the harmonious inter-relationship of features that constitute a balanced and attractive face (see Figures 2 and 3). 12…”

Section: Facial Anatomymentioning

confidence: 99%

The evolving role of hyaluronic acid fillers for facial volume restoration and contouring: a Canadian overview

Muhn

Rosen²,

Solish³

et al. 2012

CCID

View full text Add to dashboard Cite

Recent advancements, including more versatile facial fillers, refined injection techniques and the adoption of a global facial approach, have contributed to improved patient outcome and increased patient satisfaction. Nine Canadian specialists (eight dermatologists, one plastic surgeon) collaborated to develop an overview on volume restoration and contouring based on published literature and their collective clinical experience. The specialists concurred that optimal results in volume restoration and contouring depend on correcting deficiencies at various layers of the facial envelope. This includes creating a foundation for deep structural support in the supraperiosteal or submuscular plane; volume repletion of subcutaneous fat compartments; and the reestablishment of dermal and subdermal support to minimize cutaneous rhytids, grooves and furrows. It was also agreed that volume restoration and contouring using a global facial approach is essential to create a natural, youthful appearance in facial aesthetics. A comprehensive non-surgical approach should therefore incorporate combining fillers such as high-viscosity, low-molecular-weight hyaluronic acid (LMWHA) for structural support and hyaluronic acid (HA) for lines, grooves and furrows with neuromodulators, lasers and energy devices.

show abstract

Section: Facial Anatomymentioning

confidence: 99%

The evolving role of hyaluronic acid fillers for facial volume restoration and contouring: a Canadian overview

Muhn

Rosen²,

Solish³

et al. 2012

CCID

View full text Add to dashboard Cite

show abstract

“…5 All patients had facial skin depth measurements and photographs taken at baseline.All patients were seen at one-month following the initial injection. Subject inclusion criteria included a grade 2, 3 or 4 score on the Carruthers Facial Lipoatrophy Severity Scale.…”

Section: Methodmentioning

confidence: 99%

Prevention of Aerosol Contamination During Pulsatile Lavage

Marasco¹,

Sanger²,

Gordon³

et al. 2005

Plastic and Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…The FLSS is a validated four-point grading scale of FLA ranging from 1 (mild FLA) to 4 (severe FLA) (James, Carruthers, & Carruthers, 2002). Grade 0 was used to represent the condition of no FLA. QoL and depression were assessed using the Medical Outcomes Study HIV Health Survey (MOS-HIV) (Wu, Revicki, Jacobson, & Malitz, 1997), the Hospital Anxiety and Depression Scale (HADS) (Savard, Laberge, Gauthier, Ivers, & Bergeron, 1998), and the slightly modified Dermatology Quality of Life Survey (sDQLS) (Lewis & Finlay, 2004).…”

Section: Assessmentsmentioning

confidence: 99%

Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy

Antoniou¹,

Raboud

Kovacs

et al. 2009

AIDS Care

View full text Add to dashboard Cite

The long-term safety and efficacy of products used in the correction of HIV-associated facial lipoatrophy (FLA) are largely unknown. The purpose of this study was to describe the long-term efficacy and safety of polyalkylimide gel (PAIG) in the treatment of HIV-associated FLA. In this open-label, randomized, single-center study, 31 HIV-positive individuals (median age 48 years (interquartile ranges (IQR) 45, 55, 97% male) with FLA were randomized to immediate (week 0 and six) or delayed (week 12 and 18) PAIG injections. Week 96 endpoints included change in FLA severity scores (FLSS) (five-point scale), proportion of patients with adverse events, and changes in quality of life, depression and anxiety using validated surveys. Results at week 96 were available for 28 patients. Adverse events, including swelling, redness, bruising and pain, were mild, and resolved after a median of three days following the injection. At week 96, median changes in physician and patient FLSS scores were -2 (IQR -3, -1; p<0.001 vs. baseline) and -2 (IQR -2, -1; p<0.001 vs. baseline), respectively. Physician and patient FLSS scores were not significantly different between the groups at week 96. Significant improvements in patient's anxiety (p<0.001), depression (p<0.001) and mental health (p=0.01) were observed from baseline to week 96. In conclusion, treatment with PAIG was associated with sustained improvements in both the physical and psychological components of FLA through 96 weeks of follow-up.

show abstract

HIV-Associated Facial Lipoatrophy

Cited by 34 publications

References 49 publications

The evolving role of hyaluronic acid fillers for facial volume restoration and contouring: a Canadian overview

The evolving role of hyaluronic acid fillers for facial volume restoration and contouring: a Canadian overview

Prevention of Aerosol Contamination During Pulsatile Lavage

Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy

Contact Info

Product

Resources

About